Research
FORUM TRANSCRIPT

Charles River Laboratories – Non-animal In Vitro Toxicology Efforts & Q2 2022 Company Update

  • Credit
  • Healthcare
  • North America
PREMIUM

Specialist

Former director at Charles River Laboratories International Inc

Agenda

  • Charles River’s (NYSE: CRL) consolidation and investment strategy into niche analytical groups including transition to non-animal in vitro and on-a-chip models
  • Charles River’s quality and reputation among regulatory agencies and potential effects of recent FDA and EPA (Environmental Protection Agency) announcements on animal testing
  • Charles River’s service breakdown and assessment of the following segments – DSA and RMS – touching upon their strengths, gaps and positioning within each segment
  • Trickle-down effect of recent biotech funding slowdown and inflation on Charles River and additional supply chain issues
  • Competitive positioning and one-stop-shop system benefits
  • Q3 2022 outlook and future M&A and geographical expansion strategies to bolster growth

Questions

For access to this and thousands of other Transcripts, request a free trial

Request A Demo